Sigilon Therapeutics, Inc. Common Stock
SGTX
SGTX was delisted on the 10th of August, 2023.
50 hedge funds and large institutions have $52.2M invested in Sigilon Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 9 closing their positions.
75% more call options, than puts
Call options by funds: $84K | Put options by funds: $48K
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
56% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 9
11% more funds holding
Funds holding: 45 → 50 (+5)
52% less capital invested
Capital invested by funds: $109M → $52.2M (-$56.8M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$876K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$625K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$600K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$553K |
| 5 |
Renaissance Technologies
New York
|
+$392K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$2.03M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.79M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.3M |
| 4 |
Millennium Management
New York
|
-$506K |
| 5 |
Morgan Stanley
New York
|
-$483K |
SGTX Hedge Fund Activity: Q4 2021 in Review
50 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q4 2021, worth a combined $52.2M — down 52% from $109M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SGTX positions and 9 closed out — a net gain of 5 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was Bridgeway Capital Management, opening a new position worth an estimated $876K. The largest seller was American Century Companies, exiting entirely with an estimated $2.03M sold.
- 50 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q4 2021, up from 45 in Q3 2021.
- Funds reported $52.2M of Sigilon Therapeutics, Inc. Common Stock stock for Q4 2021, down 52% quarter-over-quarter.
- 14 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q4 2021 and 9 closed out, a net change of +5 holders.
- The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q4 2021 was Bridgeway Capital Management, an estimated $876K added.
- The largest Sigilon Therapeutics, Inc. Common Stock seller in Q4 2021 was American Century Companies, an estimated $2.03M sold.
Based on aggregated 13F filings for Q4 2021.